<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): February 6, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>VAXGEN, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>DELAWARE</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-26483</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>94-3236309</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>379 OYSTER POINT BOULEVARD, SUITE 10,<br>SOUTH SAN FRANCISCO, CALIFORNIA<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>94080</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(650) 624-1000</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>SECTION 8 &#150; OTHER EVENTS</B>


<P align="left" style="font-size: 10pt"><B>Item&nbsp;8.01. Other Events</B>


<P align="left" style="font-size: 10pt">On or about February&nbsp;5, 2009, Oyster Point Tech Center, LLC (&#147;Landlord&#148;), VaxGen Inc.&#146;s (&#147;VaxGen&#148; or the &#147;Company&#148;)
landlord with regard to its lease of its premises located at 349 Oyster Point Boulevard, South San Francisco,
California (the &#147;Lease&#148;), filed a complaint against the Company in the Superior Court of California for the County of
San Mateo (the &#147;Court&#148;) alleging breach of contract and termination of the Lease (the &#147;Complaint&#148;).&nbsp; In addition,
Landlord sought a writ of attachment (the &#147;Writ&#148;) or a temporary protective order (the &#147;Protective Order&#148;), for which
an ex parte hearing was held on February&nbsp;6, 2009 (the &#147;Hearing&#148;).&nbsp;


<P align="left" style="font-size: 10pt">On February&nbsp;6, 2009, in connection with the Hearing, VaxGen filed with the Court the declaration of Caroline Krumel,
the Company&#146;s controller, in support of VaxGen&#146;s opposition to the Writ and the Protective Order (the &#147;Declaration&#148;).
The Declaration included, as Exhibit&nbsp;2, an unaudited consolidated balance sheet of the Company as of January&nbsp;31, 2009,
prepared by Ms.&nbsp;Krumel (the &#147;January Balance Sheet&#148;). The January Balance Sheet reflects, among other things, VaxGen&#146;s
cash, cash equivalents and short term investments as of January&nbsp;31, 2009, in the amount of $37,872,000. A copy of the
January Balance Sheet is attached to this report as Exhibit&nbsp;99.1.


<P align="left" style="font-size: 10pt">At the Hearing, the Court denied the Writ and the Protective Order sought by Landlord. The parties are
currently in discussions to achieve an amicable resolution to the matters alleged in the Complaint and a negotiated
termination of the Lease. However, if necessary, the Company intends to vigorously defend against such allegations.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left">Exhibit</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Unaudited Consolidated Balance Sheet of VaxGen, Inc. as of January
31, 2009.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P align="left" style="margin-right:4%; font-size: 10pt"><B>SIGNATURE</B>


<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.



<P align="left" style="margin-left:45%; font-size: 10pt">VaxGen, Inc.
<BR>
(Registrant)


<P align="left" style="font-size: 10pt">Dated: February&nbsp;12, 2009



<P align="left" style="margin-left:45%; font-size: 10pt; margin-top: -11pt">By: <U><B>/</B>s/ James P. Panek&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
<BR>
James P. Panek
<BR>
President

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>EXHIBIT INDEX</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left">Exhibit</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Unaudited Consolidated Balance Sheet of VaxGen, Inc. as of January
31, 2009.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4




</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c81004e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 10375}]
{"company-data": {"conformed-name": "VAXGEN INC", "cik": "0001036968", "assigned-sic": "2834", "irs-number": "943236309", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26483", "film-number": "09594515"}, "business-address": {"street1": "379 OYSTER POINT", "street2": "SUITE 10", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080", "phone": "(650) 624-1000"}, "mail-address": {"street1": "379 OYSTER POINT", "street2": "SUITE 10", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 6, 2009
VAXGEN, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
0-26483
94-3236309
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
379 OYSTER POINT BOULEVARD, SUITE 10,
SOUTH SAN FRANCISCO, CALIFORNIA
94080
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
(650) 624-1000
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SECTION 8 – OTHER EVENTS
Item 8.01. Other Events
On or about February 5, 2009, Oyster Point Tech Center, LLC ("Landlord"), VaxGen Inc.'s ("VaxGen" or the "Company")
landlord with regard to its lease of its premises located at 349 Oyster Point Boulevard, South San Francisco,
California (the "Lease"), filed a complaint against the Company in the Superior Court of California for the County of
San Mateo (the "Court") alleging breach of contract and termination of the Lease (the "Complaint").  In addition,
Landlord sought a writ of attachment (the "Writ") or a temporary protective order (the "Protective Order"), for which
an ex parte hearing was held on February 6, 2009 (the "Hearing").
On February 6, 2009, in connection with the Hearing, VaxGen filed with the Court the declaration of Caroline Krumel,
the Company's controller, in support of VaxGen's opposition to the Writ and the Protective Order (the "Declaration").
The Declaration included, as Exhibit 2, an unaudited consolidated balance sheet of the Company as of January 31, 2009,
prepared by Ms. Krumel (the "January Balance Sheet"). The January Balance Sheet reflects, among other things, VaxGen's
cash, cash equivalents and short term investments as of January 31, 2009, in the amount of $37,872,000. A copy of the
January Balance Sheet is attached to this report as Exhibit 99.1.
At the Hearing, the Court denied the Writ and the Protective Order sought by Landlord. The parties are
currently in discussions to achieve an amicable resolution to the matters alleged in the Complaint and a negotiated
termination of the Lease. However, if necessary, the Company intends to vigorously defend against such allegations.
Item 9.01. Financial Statements and Exhibits.
Exhibit
Number
Description
99.1
Unaudited Consolidated Balance Sheet of VaxGen, Inc. as of January
31, 2009.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
VaxGen, Inc.
(Registrant)
Dated: February 12, 2009
By:
/
s/ James P. Panek
James P. Panek
President
EXHIBIT INDEX
Exhibit
Number
Description
99.1
Unaudited Consolidated Balance Sheet of VaxGen, Inc. as of January
31, 2009.